Business / Finance

RSS

Thermo Fisher Scientific acquires Life Technologies

Thermo Fisher Scientific, the world leader in serving science, today announced that it has completed its acquisition of Life Technologies Corporation (NASDAQ: LIFE) for $76.13 ($76.1311786) in cash per fully diluted common share, or approximately $13.6 billion, plus the assumption of $1.5 billion in net debt. The completion of the transaction follows the receipt of all required regulatory approvals.

4 Feb 2014

LLHC Group signs definitive stock purchase agreement with BioScrip

LHC Group Inc., a national provider of home health, hospice and comprehensive post-acute healthcare services, announced today that it has signed a definitive stock purchase agreement with BioScrip, Inc. to purchase two of its operating subsidiaries, doing business as Deaconess HomeCare and Elk Valley Health Services, for $60 million.

4 Feb 2014

Ferrer executes two agreements to support clinical studies of Lorediplon in insomnia patients

Ferrer, a privately-held Spanish pharmaceutical company, today announces that it has executed two agreements; with Ildong Pharmaceuticals Co Ltd, Korea and Ergomed Clinical Research Ltd, UK to support further clinical studies of Lorediplon in patients with insomnia.

3 Feb 2014

National Mentor Holdings enters into new senior secured credit facilities with Barclays Bank

National Mentor Holdings, Inc. today announced that it has entered into new senior secured credit facilities (the "New Senior Secured Credit Facilities") with Barclays Bank PLC, as administrative agent, and a syndicate of banks, to replace its existing senior secured credit facilities.

31 Jan 2014

Physio-Control enters into merger agreement with Sansio

Physio-Control, Inc., the world leader in emergency medical response technologies today announced it has entered into a merger agreement with Duluth, Minnesota-based Sansio - a leading provider of Software-as-a-Service (SaaS) solutions for the Emergency Medical Services (EMS) and home healthcare markets. The financial terms of the agreement were not disclosed.

31 Jan 2014

VIB and CD3 sign agreement with AstraZeneca for development of novel MALT1 inhibitors

VIB and CD3 (KU Leuven) today announced the signing of a license and collaboration agreement with AstraZeneca for the development of novel MALT1 inhibitors as therapeutics in inflammatory and oncological diseases.

31 Jan 2014

CICC signs agreement with BEUB to distribute nutriceutical products

On January 27, 2014, China Internet Cafe Holdings Group Inc. ("CICC" or the "Company") (OTCQB: CICC), a leading chain of Internet cafes in the People's Republic of China, announced that it signed a distribution agreement with Beijing Eastern Union Biopharmaceuticals, Ltd.

31 Jan 2014

Trevena prices initial public offering of common stock

Trevena, Inc., a clinical stage pharmaceutical company involved in the discovery and development of G protein coupled receptor (GPCR) biased ligands, today announced the pricing of its initial public offering of 9,250,000 shares of common stock at a price of $7.00 per share.

31 Jan 2014

AbbVie's global sales reduce 1.8% to $5.111B in fourth quarter 2013

AbbVie today announced financial results for the fourth quarter and full year ended Dec. 31, 2013.

31 Jan 2014

YODA Project enters an agreement with Johnson & Johnson to gain access to clinical trial data assets

In a move that promotes open science, the Yale University Open Data Access (YODA) Project has entered an agreement with Johnson & Johnson that will enable scientists around the world to gain access to the company's clinical trial data assets.

30 Jan 2014

Zimmer Holdings fourth quarter net sales increase 5.1% to $1.24 billion

Zimmer Holdings, Inc. today reported financial results for the quarter and year ended December 31, 2013. The Company reported fourth quarter net sales of $1.24 billion, an increase of 5.1% reported and 6.6% constant currency over the fourth quarter of 2012.

30 Jan 2014

MEDNAX reports revenue growth of 20.4% to $567M in Q4 2013

MEDNAX, Inc., the national medical group specializing in neonatal, anesthesia, maternal-fetal, pediatric cardiology and other pediatric subspecialty physician services, today reported earnings of $0.78 per share for the three months ended December 31, 2013. MEDNAX's earnings per share data reflect the impact of a two-for-one stock split that was effective December 19, 2013.

30 Jan 2014

Nanomix announces closure of private financing for $12M

Nanomix Inc., (Nanomix), a leading nanotechnology company focused on development of next generation Point of Care diagnostic tests to enable earlier and more accurate testing in hospital and pre-hospital settings, today announced that is has closed private financing for approximately $12 million.

30 Jan 2014

Alexion Pharmaceuticals reports full year 2013 GAAP and non-GAAP financial results

Alexion Pharmaceuticals, Inc. today announced financial results for the quarter and year ended December 31, 2013. For the three months ended December 31, 2013, Alexion Pharmaceuticals, Inc. ("Alexion" or the "Company") reported net product sales of Soliris® (eculizumab) of $441.9 million, compared to $320.5 million for the same period in 2012.

30 Jan 2014

Thermo Fisher Scientific fourth quarter revenue increases 6% to $3.47 billion

Thermo Fisher Scientific Inc., the world leader in serving science, today reported its financial results for the fourth quarter and full year ended December 31, 2013.

30 Jan 2014

Cardiome Pharma files shelf prospectus and registration statement

Cardiome Pharma Corp. today announced that it has filed a preliminary short form base shelf prospectus with securities regulatory authorities in Canada, other than Québec, and a corresponding shelf registration statement with the United States Securities and Exchange Commission (the "SEC") on Form F-10.

30 Jan 2014

Biogen Idec, UCB sign agreements to commercialize treatment of MS and hemophilia in Asia

Biogen Idec and UCB announced today that they have signed exclusive agreements granting UCB the right to commercialize Biogen Idec products in South Korea, Hong Kong, Thailand, Singapore, Malaysia and Taiwan, and both develop and commercialize products in China.

30 Jan 2014

Johnson & Johnson enters into novel agreement with YODA to share clinical trials data

Johnson & Johnson today announced that its subsidiary, Janssen Research and Development, LLC, has entered into a novel agreement with Yale School of Medicine's Open Data Access (YODA) Project that will extend its commitment to sharing clinical trials data to enhance public health and advance science and medicine.

30 Jan 2014

CU receives cooperative agreement to develop technological system to determine effects chemical agents

The University of Colorado Boulder has been awarded a cooperative agreement worth up to $14.6 million from the Defense Advanced Research Projects Agency (DARPA) to develop a new technological system to rapidly determine how drugs and biological or chemical agents exert their effects on human cells.

29 Jan 2014

PowerVision closes first tranche of Series D funding

PowerVision, Inc., a private company developing an accommodating intraocular lens, today announced the closing of the first tranche of its Series D funding round with participation from existing investors Venrock, Johnson & Johnson Development Corp., Medtronic, Advanced Technology Ventures, Lexington Capital and Frazier Healthcare Ventures.

28 Jan 2014

Business / Finance

Thermo Fisher Scientific acquires Life Technologies

LLHC Group signs definitive stock purchase agreement with BioScrip

Ferrer executes two agreements to support clinical studies of Lorediplon in insomnia patients

National Mentor Holdings enters into new senior secured credit facilities with Barclays Bank

Physio-Control enters into merger agreement with Sansio

VIB and CD3 sign agreement with AstraZeneca for development of novel MALT1 inhibitors

CICC signs agreement with BEUB to distribute nutriceutical products

Trevena prices initial public offering of common stock

AbbVie's global sales reduce 1.8% to $5.111B in fourth quarter 2013

YODA Project enters an agreement with Johnson & Johnson to gain access to clinical trial data assets

Zimmer Holdings fourth quarter net sales increase 5.1% to $1.24 billion

MEDNAX reports revenue growth of 20.4% to $567M in Q4 2013

Nanomix announces closure of private financing for $12M

Alexion Pharmaceuticals reports full year 2013 GAAP and non-GAAP financial results

Thermo Fisher Scientific fourth quarter revenue increases 6% to $3.47 billion

Cardiome Pharma files shelf prospectus and registration statement

Biogen Idec, UCB sign agreements to commercialize treatment of MS and hemophilia in Asia

Johnson & Johnson enters into novel agreement with YODA to share clinical trials data

CU receives cooperative agreement to develop technological system to determine effects chemical agents

PowerVision closes first tranche of Series D funding

Leveraging the Radian ASAP in standard casework

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Latest News